Navigation Links
Mylan Declares Quarterly Preferred Stock Dividend
Date:1/30/2008

PITTSBURGH, Jan. 30 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that in accordance with its 2.139 million preferred stock issuance, the Company has declared an initial quarterly dividend of $15.53 per share (based on the annual dividend rate of 6.5% and a liquidation preference of $1,000.00 per share and the time period from the date of issuance to February 15, 2008) payable on February 15, 2008 to holders of preferred stock of record as of February 1, 2008.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
2. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
3. Mylan Sets Date of 2008 Annual Meeting
4. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
5. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
6. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
7. Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock
8. Mylan Announces Appointment of Joseph F. Haggerty as Senior Vice President and Global General Counsel
9. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
10. Mylan Settles Its First-to-File Opportunity on Levetiracetam with UCB
11. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Atlanta, GA (PRWEB) , ... ... ... information technology and security executive networking and relationship-marketing firm, announced today that ... for the 2017 Information Security Executive® (ISE®) Central Awards. , Awards include ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” which can ... 6th, sparks a conversation about epilepsy, bearing down on the social stigma and ... be diagnosed with epilepsy within their lifetime. With such a large percentage of ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... announced that the company will provide alerting technology to Central Illinois Health ... awarded $1.7 million in federal funds as the sole sub-recipient participating with ...
(Date:12/5/2016)... ... December 05, 2016 , ... Dr. Barry M. Weintraub, one of New ... recently participated in the 36th Annual Cutting Edge Aesthetic Symposium at the Waldorf Astoria ... getting that perfect, yet natural-looking, nose. Dr. Weintraub, who is world-renowned for his expertise ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... for the Florida Hospital West Florida Region. McGuinness brings experience in executive leadership ... engaging staff, physicians and leaders. , In her new role, that officially begins ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, ... Commercialization of Public Research (the Florida Institute) ... agreement SegAna, LLC, an Orlando ... Central Florida. The Florida Institute supports new company ... funding gaps for companies spinning out of Florida-based universities ...
(Date:12/5/2016)... Dec. 5, 2016  Breckenridge Pharmaceutical, Inc. announced ... marketing agreement with development and manufacturing partner Gland ... the terms of this agreement, Breckenridge will market ... the United States . The ... ANDA. The products cover a wide range of ...
(Date:12/5/2016)... 2016  Sharn Anesthesia Inc. announced today that it ... partner for Salter Labs.  The company also received the ... of outstanding sales performance. Salter Labs is ... care, including the market gold standard ECO 2 ... of the Parker Flex-Tip® Endotracheal Tube, which is a ...
Breaking Medicine Technology: